face to face
“WE PLAN TO STRENGTHEN OUR DIABETES
PRODUCT PORTFOLIO BY 2018”
Eli Lilly and Company is among the major players in the Indian insulin
market. Having started Indian operations way back in 1993, the company
has seen consistent growth over the period of time. Utilizing effective
marketing strategy, Eli Lilly India has witnessed continuous expansion of
its business operations resulting into increased market share. In an
exclusive conversation with the Biovoice, Mr Edgard A. Olaizola,
Managing Director, Eli Lilly India shared insights on the company’s
operations in the country besides views on various healthcare related
issues. Read the excerpts below:
BY RAHUL KOUL
Mr Edgard A. Olaizola serves as
the Managing Director of Eli Lilly
and Company (India) since
September 1, 2013. Mr Olaizola
has with him over 13 years of
diversified experience in Lilly,
with a host of senior level
positions to his credit across
different markets, including US,
Canada, Peru, Ecuador and
Bolivia. His last role was as
General Manager, Lilly Taiwan,
where he played a crucial role in
making Lilly Taiwan as one of the
best performing countries for Lilly
in Asia region. Mr Olaizola holds a
degree in Economics from
Universidad Catolica Andres Bello
and has completed his Post
Graduation in Business
Management from Washington
University in St. Louis.
10
BioVoiceNews | November 2016